Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$913000.0.

  • Century Therapeutics' Net Cash Flow fell 10819.57% to -$913000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 27486.52%. This contributed to the annual value of $11.9 million for FY2024, which is 13224.06% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Net Cash Flow is -$913000.0, which was down 10819.57% from $4.9 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Net Cash Flow high stood at $69.6 million for Q1 2022, and its period low was -$27.1 million during Q4 2022.
  • Moreover, its 4-year median value for Net Cash Flow was -$1.4 million (2022), whereas its average is $34133.3.
  • As far as peak fluctuations go, Century Therapeutics' Net Cash Flow surged by 22198.86% in 2024, and later crashed by 118378.91% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Net Cash Flow stood at -$27.1 million in 2022, then soared by 70.53% to -$8.0 million in 2023, then soared by 172.42% to $5.8 million in 2024, then plummeted by 115.79% to -$913000.0 in 2025.
  • Its Net Cash Flow stands at -$913000.0 for Q3 2025, versus $4.9 million for Q2 2025 and -$6.6 million for Q1 2025.